Hormone Optimization After 40 for Longevity: Labs, Lifestyle, and Therapy Boundaries

This article is for men and women over 40 who have symptoms they suspect are hormonal and want to know where the evidence actually stops. Fatigue, low libido, poor recovery, hot flashes, brain fog, and stalled body composition all get attributed to hormones. Some of those attributions are correct. Most are not. The useful question is not "how do I optimize my hormones" but "do I have a diagnosable endocrine condition, and if not, which behaviors are producing these symptoms?" Those are two different investigations with different tools, different timelines, and very different risk profiles.

The commercial environment around this topic is unusually distorted. Direct-to-consumer clinics sell testosterone, pellets, compounded blends, and peptide packages on the strength of a single lab draw and a symptom questionnaire. The 2018 Endocrine Society clinical practice guideline is explicit that testosterone therapy is not recommended for age-related decline in serum testosterone in otherwise healthy older men who lack symptomatic hypogonadism. That is a direct contradiction of how most of the industry operates. You should read any clinic that skips diagnosis and moves straight to prescribing as a business model, not a standard of care.

Set your expectations before you start. No randomized human trial has shown that any hormone therapy extends lifespan. The outcome data that exist are about symptoms, bone density, body composition, and safety, and they apply to defined clinical populations rather than to healthy adults chasing better numbers. Everything in this article is educational. Diagnosis, prescribing, and monitoring for anything hormonal belong to a clinician who can examine you, order the right tests, and take responsibility for the follow-up. If you want a definitive answer about your own hormones, this article will not give you one, and neither will a home test kit.

The underlying biology is real and well described. In men, total testosterone declines gradually with age, and sex hormone binding globulin tends to rise, so free testosterone often falls faster than total. In women, the menopause transition is not gradual. Estradiol production drops over a few years, and the symptom burden clusters around that window. Thyrotropin distributions shift upward with age, which means more older adults cross a lab cutoff without having thyroid disease. Growth hormone secretion and DHEA sulfate both decline steadily from early adulthood. All of that is established. None of it establishes that replacing a declining hormone improves how long or how well you live.

Sort the interventions by what has actually been tested. Menopausal hormone therapy has randomized outcome data and remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, with demonstrated prevention of bone loss and fracture. Testosterone in men with confirmed hypogonadism has randomized data too. The Testosterone Trials randomized 790 men aged 65 and older with testosterone below 275 ng/dL and found moderate benefit for sexual function, a small walking-distance effect, and no benefit for vitality or fatigue. That is a narrower result than the marketing suggests.

Now the other direction. Growth hormone in healthy older adults has been tested and did not pass. A systematic review of 18 randomized trials in 508 participants found roughly two kilograms of fat loss and two kilograms of lean mass gain with no weight change, alongside significantly higher rates of soft tissue edema, arthralgia, carpal tunnel syndrome, and gynecomastia. The authors concluded growth hormone cannot be recommended as an anti-aging therapy. DHEA at 50 mg daily for a year in 225 adults aged 55 to 85 produced no benefit for cognition or well-being. Growth hormone secretagogue peptides sold by wellness clinics have no randomized human outcome data at all.

Sequence matters because the behaviors come first in both directions. They change symptoms, and they change the labs you are about to interpret. Testing a man who has been sleeping five hours a night, drinking most evenings, and running a large calorie deficit produces a low testosterone value that reflects his current physiology rather than a permanent endocrine condition. The order that keeps you out of trouble is sleep, then protein and resistance training, then body fat and alcohol, then targeted medical evaluation. Skipping to the last step is how people end up on lifelong therapy for a reversible problem.

Make the behavior targets concrete enough that you can tell whether you actually did them. Anchor sleep first with a fixed wake time seven days a week, weekends included, and a lights-out time far enough ahead of it that you are not running on an alarm and caffeine by midweek. For protein, a meta-analysis of resistance training trials found that gains in fat-free mass plateaued once total intake reached about 1.62 grams per kilogram of body weight per day, so treat roughly 1.6 g/kg as a floor distributed across meals rather than a target you hit twice a week. See Protein Targets for Longevity After 40: A Practical Weekly Blueprint for how to build that intake without living on shakes. Cap alcohol, or remove it for the block, because it degrades sleep architecture and confounds everything downstream.

Be equally clear about what behavior cannot do. Lifestyle change does not reverse menopause. It does not cure primary hypogonadism, primary hypothyroidism, or a pituitary lesion. If you have a symptom pattern that suggests real endocrine disease, including new visual field changes, galactorrhea, testicular atrophy, unexplained anemia, or rapid unintentional weight change, that is not a twelve-week self-experiment. That is a clinician appointment now. The sequencing logic in this article applies to the common ambiguous case, not to red flags. The behaviors still help in those cases. They just stop being the first move.

Spend weeks one and two on baseline capture and nothing else. Record the specific symptoms you want to change rather than a general sense of feeling off. For men that usually means libido, morning erections, training performance, and energy across the day. For women in the menopause transition it means hot flash and night sweat frequency, sleep interruptions, mood, and vaginal or urinary symptoms. Add waist circumference, body weight, and a weekly average of sleep duration. Vague symptoms produce vague conclusions, and you cannot evaluate a change you never described precisely.

Weeks three through eight are execution with a deliberately boring rule. Change one thing at a time, and add no new supplements during the block. Hold resistance training at two to three sessions per week with progressive overload, because that is the intervention with the most reliable effect on the body composition and functional outcomes people usually attribute to hormones. See Strength Training After 40: The Longevity Blueprint for programming that survives a real schedule. If sleep or training quality falls apart for more than a week, fix that before adding anything else. Adding a second variable while the first one is failing guarantees you will not know which change did what.

Weeks nine through twelve are where you decide. Re-score the same symptom list against your baseline. If the symptom burden has meaningfully improved, you have your answer and no testing is required. If it has not, book a clinician and bring the log with you. Do not order a hormone panel from a marketing site and interpret it yourself. Testosterone follows a diurnal rhythm with peak values in the morning, and glucose and food intake suppress it, which is why the timing and fasting state of the draw determine whether the number means anything.

For men, the diagnostic pathway is specific. The Endocrine Society guideline recommends measuring fasting morning total testosterone as the initial test and confirming the diagnosis by repeating that measurement on a second morning. When total testosterone sits near the lower limit or when conditions that alter sex hormone binding globulin are present, free testosterone becomes relevant. Luteinizing hormone and follicle stimulating hormone are measured to distinguish primary from secondary hypogonadism, which changes both the workup and the treatment decision. A single afternoon draw is not a diagnosis, and neither is a symptom score plus one borderline value.

For women, resist the urge to build the decision around a hormone panel. Menopause is diagnosed clinically from menstrual history and symptoms. Follicle stimulating hormone and estradiol fluctuate substantially during perimenopause, so a single draw can be misleading in either direction. The decision that matters is whether symptoms are bothersome enough to warrant treatment and whether you fall inside the window where the benefit-risk balance is favorable. Thyroid and iron status are worth checking in the same visit, because both produce overlapping symptoms and both are treatable. Menopause and Longevity: Evidence-Based Strategies That Work covers the symptom-side decisions in more detail.

Thyroid deserves its own caution because it is the most over-treated item on this list. Thyrotropin is variable, and a single mildly elevated value should be repeated before anything is prescribed. In older adults with mildly elevated thyrotropin and normal free thyroxine, randomized evidence does not support routine treatment. The TRUST trial randomized 737 adults aged 65 and over with thyrotropin between 4.6 and 19.99 mIU/L and found no clinical difference in hypothyroid symptom or tiredness scores after twelve months of levothyroxine. A US Preventive Services Task Force review of treatment versus placebo trials likewise found no significant clinical benefit in grade 1 subclinical hypothyroidism. Track fasting insulin, HbA1c, waist circumference, and body composition alongside any hormone value, and read direction over months rather than reacting to single results. Best Longevity Blood Tests to Track Your Health covers panel selection.

Testosterone therapy has a defined list of situations where it should not be started. The Endocrine Society guideline recommends against therapy in men planning fertility in the near term, and in men with breast or prostate cancer, a palpable prostate nodule or induration, PSA above 4 ng/mL or above 3 ng/mL in men at high prostate cancer risk, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the previous six months, or thrombophilia. Monitoring is not optional. Check hematocrit at baseline, at three to six months, and annually thereafter. If hematocrit exceeds 54 percent, therapy is stopped until it returns to a safe range, the patient is evaluated for hypoxia and sleep apnea, and treatment is restarted at a reduced dose if at all.

The cardiovascular question was tested directly. TRAVERSE randomized 5,246 middle-aged and older men with hypogonadism and either established cardiovascular disease or high cardiovascular risk, mean age 63.3 years, to transdermal testosterone or placebo. Testosterone was noninferior to placebo for major adverse cardiac events. That is a meaningful reassurance for men who have a genuine indication. It is not evidence of benefit, and the trial also produced safety signals including a small increase in atrial fibrillation and non-fatal arrhythmias. Higher rates of pulmonary embolism and acute kidney injury were recorded as well, though the European expert panel reviewing the trial attributes those signals largely to COVID-19 infection within the cohort rather than to testosterone. Fertility suppression is a separate and often underexplained consequence, because exogenous testosterone suppresses the signals that drive sperm production.

For menopausal hormone therapy, the decision gate is timing. The 2022 position statement of The North American Menopause Society describes a favorable benefit-risk ratio for treating bothersome vasomotor symptoms and preventing bone loss in women under 60 or within 10 years of menopause onset who have no contraindications. Beyond that window the balance becomes less favorable because the absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are higher. Hormone therapy is not government approved for prevention of cardiovascular disease, and it should not be started for that purpose. The contraindications the statement names are unexplained vaginal bleeding, liver disease, prior estrogen-sensitive cancer including breast cancer, prior coronary heart disease, stroke, myocardial infarction or venous thromboembolism, and a personal history or inherited high risk of thromboembolic disease. Read those last two carefully: a clot, a heart attack, or a stroke counts even if it was years ago, and an inherited clotting risk counts even if you have never had an event. Unexplained bleeding has to be worked up before any estrogen is started. Every one of these decisions requires a prescribing clinician.

The most common failure is treating a number instead of a person. One low-normal testosterone value, drawn in the afternoon, in a man with untreated sleep apnea, is not a diagnosis of hypogonadism. Neither is a thyrotropin of 5.2 mIU/L with normal free thyroxine in a 62-year-old with no symptoms. Both get treated constantly. The second failure is the mirror image: dismissing genuinely disabling symptoms because a single lab came back inside the reference range. Reference ranges describe populations, not individuals, which is why the guidelines pair biochemical confirmation with symptoms rather than relying on either alone.

The third failure pattern is the clinic bundle. Pellets, compounded multi-hormone blends, growth hormone secretagogue peptides, and DHEA are frequently sold together as "optimization," usually as a membership that folds the prescription, the labs, and the follow-up into one recurring price. The randomized evidence for the last two, covered above, is null for DHEA and net-negative for growth hormone, and peptide secretagogues have no randomized human outcome data at all. The compounded component has its own problem: the NAMS position statement flags compounded bioidentical preparations for minimal government regulation and monitoring, overdosing and underdosing, and impurities, which makes a custom blend a step away from a product with known contents rather than a step toward a personalized one. Ask any clinic selling the bundle which component has a randomized trial behind it, what that trial measured, and how long it ran.

If you are already on therapy and symptoms have not improved, the diagnosis is the thing to question first. Untreated sleep apnea, iron deficiency, depression, chronic underfueling, heavy alcohol use, and unmanaged thyroid disease all produce the symptom cluster people attribute to low hormones, and none of them respond to hormone therapy. Sleep is the highest-yield place to start, and Sleep Optimization for Longevity: The 80/20 System covers the specifics. Rising hematocrit, rising blood pressure, new leg swelling, chest symptoms, or shortness of breath are reasons to contact your clinician rather than adjust your own dose.

Rank the levers honestly. Resistance training, protein adequacy, sleep regularity, aerobic fitness, and visceral fat reduction have larger and better-documented effects on the outcomes people want from hormone therapy than hormone therapy has in adults without a diagnosis. That is not a rhetorical dodge. It is what the trial evidence shows when you compare the size and certainty of the effects. Hormone therapy is a targeted treatment for a defined clinical problem. It works well inside that scope and poorly outside it. Building the base first also means that if you do eventually need therapy, you will be able to tell whether it worked.

Treat this article as one component of a wider protocol rather than a standalone plan. If you are a man weighing whether your symptoms warrant evaluation, Testosterone and Longevity in Men: Evidence, Risks, and Monitoring goes deeper on that specific decision. The honest summary is short. Fix the behaviors first, test properly and twice if you test at all, involve a clinician for anything prescription or diagnostic, and be suspicious of anyone who promises that a hormone will extend your life. That claim has not been demonstrated in humans, and pretending otherwise is where most of the harm in this category comes from.